welcome Welcome

“May all be happy, may all be healed, may all be at peace and may no one ever suffer."


Drug International Ltd.

N/A, N/A
...
Drug International Ltd.
Loading...

Cyphos 200mg / vial

Size: 200 mg vial Price: 150.00
IV Infusion IV Infusion
Cyclophosphamide
Cytotoxic Chemotherapy
0.00 (0)



Alternate Strengths


Generic for Diseases

Generic Indications
  • Acute Lymphocytic Leukemia
  • Acute myeloid leukemia
  • Behcets syndrome
  • Benign prostatic hyperplasia (BPH)
  • Bladder carcinoma
  • Bone malignancies
  • Breast cancer and bone metastases
  • Breast carcinoma
  • Carcinoma
  • Diffuse scleroderma
  • Follicular lymphoma
  • Hodgkins disease
  • Hodgkins lymphoma
  • Lymphocytic leukemia
  • Lymphoma
  • Metastatic breast carcinoma
  • Multiple myeloma
  • Multiple sclerosis
  • Myasthenia gravis
  • Nephrosis
  • Nephrotic syndrome
  • Neuroblastoma
  • Non-small cell lung cancer
  • Ovarian carcinoma
  • Polymyositis
  • Pyoderma gangrenosum
  • Retinoblastoma
  • Rheumatoid Arthritis (RA)
  • SLE
  • Scleritis
  • Severe erythema multiforme (Stevens-Johnson syndrome)
  • Small cell lung cancer
  • Stevens-Johnson syndrome
  • Systemic lupus erythematosus (SLE)
  • Systemic sclerosis
  • Vasculitis

Generic Description

Cyclophosphamide is a prodrug which is converted in the body to the active metabolites. It acts at any stage of the cell cycle. It prevents cell division by cross-linking deoxyribonucleic acid (DNA) strands and reducing DNA synthesis. It also exerts a potent immunosuppressive effect.


Component

Drug Indication

Malignant Diseases:

Cyclophosphamide is indicated for the treatment of:

  • Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma
  • Multiple myeloma
  • Leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenousand monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration)
  • Mycosis fungoides (advanced disease)
  • Neuroblastoma (disseminated disease)
  • Adenocarcinoma of the ovary
  • Retinoblastoma
  • Carcinoma of the breast

Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs.

Minimal Change Nephrotic Syndrome in Pediatric Patients:

Cyclophosphamide is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy.


Dosage Administration

Intravenous (Adult)-

Malignancies: 

  • Low dose regimen: 2-6 mg/kg wkly as a single dose;
  • Moderate dose regimen: 10-15 mg/kg wkly as a single dose;
  • High dose regimen: 20-40 mg/kg as a single dose every 10-20 days.

Alternatively,

  • 80-300 mg/m2 daily as a single dose, or
  • 300-600 mg/m2 wkly as a single dose, or
  • 600-1,500 mg/m2 as a single dose or
  • Short infusion at 10- to 20-day intervals.

Oral (Child)-

Nephrotic syndrome: 

  • 2 mg/kg daily for 8-12 wk.
  • Max cumulative dose: 168 mg/kg.
  • Max duration: 90 days.

Oral (Adult)-

Malignancies: 

  • Low dose regimen: 2-6 mg/kg wkly in divided dose.
  • Alternatively, 100-300 mg daily in divided doses, or
  • 50-250 mg/m2 daily or 80-300 mg/m2 daily in divided doses.

Administration

Should be taken on an empty stomach. Preferably taken on an empty stomach, but may be taken with meals to minimise GI irritation. Ensure adequate fluid intake. Swallow whole.


Contraindication

Patient with bone marrow aplasia, urinary outflow obstruction, UTI, acute infection, drug- or radiation-induced urothelial toxicity. Pregnancy.


Side Effect

Alopecia, skin and nails hyperpigmentation, nausea and vomiting, mucositis, inappropriate antidiuretic hormone secretion, carbohydrate metabolism disturbances, gonadal suppression, interstitial pulmonary fibrosis.

Overdose Effects

Symptoms: Urotoxicity, myelosuppression, cardiotoxicity (including cardiac failure), stomatitis, veno-occlusive hepatic disease.

Management: Supportive treatment. May consider haemodialysis. Cystitis prophylaxis with mesna may be useful for urotoxicity.


Precaution Warning

Patient with DM, severe immunosuppression, acute porphyria, pre-existing CV disease or those at risk for cardiotoxicity. Renal and hepatic impairment. Lactation.

Pregnancy & Lactation

Pregnancy Category D. There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).





Store

Cyphos 200mg / vial and more Available Brands


...
Cardizem 60mg
Diltiazem Hydrochloride (FC tablet)
Tablet
S: 100 , P: 500.00
...
Ticlopid 250mg
Ticlopidine Hydrochloride
Tablet
S: 30 , P: 210.00
...
Prolacto 4billion
Probiotic Combination [4 Billion]
Capsule
S: 32s pack , P: 512.00
...
Flupen 250mg
Flucloxacillin Sodium
Capsule
S: 70 , P: 350.00
...
Cefaking 2gm / vial
Cefoperazone Sodium
IM/IV Injection
S: 2 gm vial , P: 400.00
...
Diretic 20mg + 50m...
Furosemide + Spironolactone
Tablet
S: 56 , P: 392.00
...
Entavir 1mg
Entecavir
Tablet
S: 10 , P: 903.00
...
Mecolin 500mcg
Mecobalamin
Tablet
S: 50 , P: 202.50

Searching Keywords Idea
...

Bangladesh is Number One in Digital Medical Management.
To be happy, beautiful, healthy, wealthy, hale and long-lived stay with DM3S.